{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:27:37Z","timestamp":1792783657434,"version":"4.5.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T00:00:00Z","timestamp":1684972800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T00:00:00Z","timestamp":1684972800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Research Foundation for Advanced Talents of Fujian Medical University","award":["XRCZX2017020"],"award-info":[{"award-number":["XRCZX2017020"]}],"id":[{"id":"https:\/\/ror.org\/050s6ns64","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Research Foundation for Advanced Talents of Fujian Medical University","award":["XRCZX2019005"],"award-info":[{"award-number":["XRCZX2019005"]}],"id":[{"id":"https:\/\/ror.org\/050s6ns64","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Beijing Natural Science Foundation","award":["7192198"],"award-info":[{"award-number":["7192198"]}]},{"name":"Strategic Priority Research Program of Chinese Academy of Sciences","award":["XDB36000000"],"award-info":[{"award-number":["XDB36000000"]}],"id":[{"id":"https:\/\/ror.org\/034t30j35","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Strategic Priority Research Program of Chinese Academy of Sciences","award":["XDB38010400"],"award-info":[{"award-number":["XDB38010400"]}],"id":[{"id":"https:\/\/ror.org\/034t30j35","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["32027801"],"award-info":[{"award-number":["32027801"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["31870992"],"award-info":[{"award-number":["31870992"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["21775031"],"award-info":[{"award-number":["21775031"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"the Natural Science Foundation of Fujian Province","award":["2022J01203"],"award-info":[{"award-number":["2022J01203"]}]},{"name":"CAS-JSPS","award":["GJHZ2094"],"award-info":[{"award-number":["GJHZ2094"]}]},{"name":"Science and Technology Service Network Initiative of the Chinese Academy of Sciences","award":["KFJ-STS-ZDTP-079"],"award-info":[{"award-number":["KFJ-STS-ZDTP-079"]}],"id":[{"id":"https:\/\/ror.org\/034t30j35","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1007\/s10549-023-06972-6","type":"journal-article","created":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T00:02:47Z","timestamp":1684972967000},"page":"281-291","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Efficacy relevance of PD-L1 expression on circulating tumor cells in metastatic breast cancer patients treated with anti-PD-1 immunotherapy"],"prefix":"10.1007","volume":"200","author":[{"given":"Ying","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinmei","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaopeng","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoyuan","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuejie","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anqi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2212-0268","authenticated-orcid":false,"given":"Zhiyuan","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanlian","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zefei","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2823-7937","authenticated-orcid":false,"given":"Tao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,25]]},"reference":[{"issue":"1","key":"6972_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21708","volume":"72","author":"RL Siegel","year":"2022","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A (2022) Cancer statistics. CA Cancer J Clin 72(1):7\u201333. https:\/\/doi.org\/10.3322\/caac.21708","journal-title":"CA Cancer J Clin"},{"key":"6972_CR2","doi-asserted-by":"publisher","first-page":"175883592094092","DOI":"10.1177\/1758835920940928","volume":"12","author":"Y Zou","year":"2020","unstructured":"Zou Y, Zou X, Zheng S, Tang H, Zhang L, Liu P, Xie X (2020) Efficacy and predictive factors of immune checkpoint inhibitors in metastatic breast cancer: a systematic review and meta-analysis. Ther Adv Med Oncol 12:1758835920940928. https:\/\/doi.org\/10.1177\/1758835920940928","journal-title":"Ther Adv Med Oncol"},{"issue":"19","key":"6972_CR3","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1056\/NEJMoa1701830","volume":"377","author":"H Pan","year":"2017","unstructured":"Pan H, Gray R, Braybrooke J, Davies C, Taylor C, McGale P, Peto R, Pritchard KI, Bergh J, Dowsett M, Hayes DF (2017) 20-Year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years. N Engl J Med 377(19):1836\u20131846. https:\/\/doi.org\/10.1056\/NEJMoa1701830","journal-title":"N Engl J Med"},{"key":"6972_CR4","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.breast.2021.02.009","volume":"57","author":"EM Salvo","year":"2021","unstructured":"Salvo EM, Ramirez AO, Cueto J, Law EH, Situ A, Cameron C, Samjoo IA (2021) Risk of recurrence among patients with HR-positive, HER2-negative, early breast cancer receiving adjuvant endocrine therapy: a systematic review and meta-analysis. Breast 57:5\u201317. https:\/\/doi.org\/10.1016\/j.breast.2021.02.009","journal-title":"Breast"},{"issue":"6","key":"6972_CR5","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1634\/theoncologist.2014-0002","volume":"19","author":"M Bonotto","year":"2014","unstructured":"Bonotto M, Gerratana L, Poletto E, Driol P, Giangreco M, Russo S, Minisini AM, Andreetta C, Mansutti M, Pisa FE, Fasola G, Puglisi F (2014) Measures of outcome in metastatic breast cancer: insights from a real-world scenario. Oncologist 19(6):608\u2013615. https:\/\/doi.org\/10.1634\/theoncologist.2014-0002","journal-title":"Oncologist"},{"issue":"22","key":"6972_CR6","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1056\/NEJMoa1809615","volume":"379","author":"P Schmid","year":"2018","unstructured":"Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H, Dieras V, Hegg R, Im SA, Shaw Wright G, Henschel V, Molinero L, Chui SY, Funke R, Husain A, Winer EP, Loi S, Emens LA, Investigators IMT (2018) Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med 379(22):2108\u20132121. https:\/\/doi.org\/10.1056\/NEJMoa1809615","journal-title":"N Engl J Med"},{"issue":"15 Pt 1","key":"6972_CR7","doi-asserted-by":"publisher","first-page":"4429","DOI":"10.1158\/1078-0432.CCR-06-3045","volume":"13","author":"R Dent","year":"2007","unstructured":"Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P, Narod SA (2007) Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 13(15 Pt 1):4429\u20134434. https:\/\/doi.org\/10.1158\/1078-0432.CCR-06-3045","journal-title":"Clin Cancer Res"},{"issue":"3","key":"6972_CR8","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1001\/jama.2018.19323","volume":"321","author":"AG Waks","year":"2019","unstructured":"Waks AG, Winer EP (2019) Breast cancer treatment: a review. JAMA 321(3):288\u2013300. https:\/\/doi.org\/10.1001\/jama.2018.19323","journal-title":"JAMA"},{"key":"6972_CR9","doi-asserted-by":"publisher","first-page":"107886","DOI":"10.1016\/j.intimp.2021.107886","volume":"98","author":"K Barzaman","year":"2021","unstructured":"Barzaman K, Moradi-Kalbolandi S, Hosseinzadeh A, Kazemi MH, Khorramdelazad H, Safari E, Farahmand L (2021) Breast cancer immunotherapy: current and novel approaches. Int Immunopharmacol 98:107886. https:\/\/doi.org\/10.1016\/j.intimp.2021.107886","journal-title":"Int Immunopharmacol"},{"key":"6972_CR10","doi-asserted-by":"publisher","first-page":"779691","DOI":"10.3389\/fimmu.2022.779691","volume":"13","author":"A Chennamadhavuni","year":"2022","unstructured":"Chennamadhavuni A, Abushahin L, Jin N, Presley CJ, Manne A (2022) Risk factors and biomarkers for immune-related adverse events: a practical guide to identifying high-risk patients and rechallenging immune checkpoint inhibitors. Front Immunol 13:779691. https:\/\/doi.org\/10.3389\/fimmu.2022.779691","journal-title":"Front Immunol"},{"issue":"5","key":"6972_CR11","doi-asserted-by":"publisher","first-page":"4019","DOI":"10.1007\/s00520-022-06826-9","volume":"30","author":"KS Gunturu","year":"2022","unstructured":"Gunturu KS, Pham TT, Shambhu S, Fisch MJ, Barron JJ, Debono D (2022) Immune checkpoint inhibitors: immune-related adverse events, healthcare utilization, and costs among commercial and Medicare Advantage patients. Support Care Cancer 30(5):4019\u20134026. https:\/\/doi.org\/10.1007\/s00520-022-06826-9","journal-title":"Support Care Cancer"},{"issue":"6","key":"6972_CR12","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/s41571-021-00473-5","volume":"18","author":"DB Doroshow","year":"2021","unstructured":"Doroshow DB, Bhalla S, Beasley MB, Sholl LM, Kerr KM, Gnjatic S, Wistuba II, Rimm DL, Tsao MS, Hirsch FR (2021) PD-L1 as a biomarker of response to immune-checkpoint inhibitors. Nat Rev Clin Oncol 18(6):345\u2013362. https:\/\/doi.org\/10.1038\/s41571-021-00473-5","journal-title":"Nat Rev Clin Oncol"},{"issue":"9","key":"6972_CR13","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1093\/annonc\/mdz196","volume":"30","author":"P Hofman","year":"2019","unstructured":"Hofman P, Heeke S, Alix-Panabieres C, Pantel K (2019) Liquid biopsy in the era of immuno-oncology: is it ready for prime-time use for cancer patients? Ann Oncol 30(9):1448\u20131459. https:\/\/doi.org\/10.1093\/annonc\/mdz196","journal-title":"Ann Oncol"},{"key":"6972_CR14","doi-asserted-by":"publisher","first-page":"102257","DOI":"10.1016\/j.ctrv.2021.102257","volume":"99","author":"C Boman","year":"2021","unstructured":"Boman C, Zerdes I, Martensson K, Bergh J, Foukakis T, Valachis A, Matikas A (2021) Discordance of PD-L1 status between primary and metastatic breast cancer: a systematic review and meta-analysis. Cancer Treat Rev 99:102257. https:\/\/doi.org\/10.1016\/j.ctrv.2021.102257","journal-title":"Cancer Treat Rev"},{"issue":"3","key":"6972_CR15","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1515\/jtim-2017-0029","volume":"5","author":"Y Wang","year":"2017","unstructured":"Wang Y, Zhou Y, Hu Z (2017) The functions of circulating tumor cells in early diagnosis and surveillance during cancer advancement. J Transl Int Med 5(3):135\u2013138. https:\/\/doi.org\/10.1515\/jtim-2017-0029","journal-title":"J Transl Int Med"},{"issue":"8","key":"6972_CR16","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1056\/NEJMoa040766","volume":"351","author":"M Cristofanilli","year":"2004","unstructured":"Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, Reuben JM, Doyle GV, Allard WJ, Terstappen LW, Hayes DF (2004) Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 351(8):781\u2013791. https:\/\/doi.org\/10.1056\/NEJMoa040766","journal-title":"N Engl J Med"},{"issue":"7","key":"6972_CR17","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1200\/JCO.2005.08.140","volume":"23","author":"M Cristofanilli","year":"2005","unstructured":"Cristofanilli M, Hayes DF, Budd GT, Ellis MJ, Stopeck A, Reuben JM, Doyle GV, Matera J, Allard WJ, Miller MC, Fritsche HA, Hortobagyi GN, Terstappen LW (2005) Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. J Clin Oncol 23(7):1420\u20131430. https:\/\/doi.org\/10.1200\/JCO.2005.08.140","journal-title":"J Clin Oncol"},{"issue":"14 Pt 1","key":"6972_CR18","doi-asserted-by":"publisher","first-page":"4218","DOI":"10.1158\/1078-0432.CCR-05-2821","volume":"12","author":"DF Hayes","year":"2006","unstructured":"Hayes DF, Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Miller MC, Matera J, Allard WJ, Doyle GV, Terstappen LW (2006) Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clin Cancer Res 12(14 Pt 1):4218\u20134224. https:\/\/doi.org\/10.1158\/1078-0432.CCR-05-2821","journal-title":"Clin Cancer Res"},{"issue":"21","key":"6972_CR19","doi-asserted-by":"publisher","first-page":"6403","DOI":"10.1158\/1078-0432.CCR-05-1769","volume":"12","author":"GT Budd","year":"2006","unstructured":"Budd GT, Cristofanilli M, Ellis MJ, Stopeck A, Borden E, Miller MC, Matera J, Repollet M, Doyle GV, Terstappen LW, Hayes DF (2006) Circulating tumor cells versus imaging\u2013predicting overall survival in metastatic breast cancer. Clin Cancer Res 12(21):6403\u20136409. https:\/\/doi.org\/10.1158\/1078-0432.CCR-05-1769","journal-title":"Clin Cancer Res"},{"key":"6972_CR20","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1186\/1471-2407-13-202","volume":"13","author":"Y Liu","year":"2013","unstructured":"Liu Y, Liu Q, Wang T, Bian L, Zhang S, Hu H, Li S, Hu Z, Wu S, Liu B, Jiang Z (2013) Circulating tumor cells in HER2-positive metastatic breast cancer patients: a valuable prognostic and predictive biomarker. BMC Cancer 13:202. https:\/\/doi.org\/10.1186\/1471-2407-13-202","journal-title":"BMC Cancer"},{"issue":"11","key":"6972_CR21","doi-asserted-by":"publisher","first-page":"2766","DOI":"10.1093\/annonc\/mdt246","volume":"24","author":"ZF Jiang","year":"2013","unstructured":"Jiang ZF, Cristofanilli M, Shao ZM, Tong ZS, Song EW, Wang XJ, Liao N, Hu XC, Liu Y, Wang Y, Zeng L, Zhang M (2013) Circulating tumor cells predict progression-free and overall survival in Chinese patients with metastatic breast cancer, HER2-positive or triple-negative (CBCSG004): a multicenter, double-blind, prospective trial. Ann Oncol 24(11):2766\u20132772. https:\/\/doi.org\/10.1093\/annonc\/mdt246","journal-title":"Ann Oncol"},{"key":"6972_CR22","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1186\/s12885-016-2578-5","volume":"16","author":"S Zhang","year":"2016","unstructured":"Zhang S, Li L, Wang T, Bian L, Hu H, Xu C, Liu B, Liu Y, Cristofanilli M, Jiang Z (2016) Real-time HER2 status detected on circulating tumor cells predicts different outcomes of anti-HER2 therapy in histologically HER2-positive metastatic breast cancer patients. BMC Cancer 16:526. https:\/\/doi.org\/10.1186\/s12885-016-2578-5","journal-title":"BMC Cancer"},{"key":"6972_CR23","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.breast.2017.01.007","volume":"32","author":"XR Liu","year":"2017","unstructured":"Liu XR, Shao B, Peng JX, Li HP, Yang YL, Kong WY, Song GH, Jiang HF, Liang X, Yan Y (2017) Identification of high independent prognostic value of nanotechnology based circulating tumor cell enumeration in first-line chemotherapy for metastatic breast cancer patients. Breast 32:119\u2013125. https:\/\/doi.org\/10.1016\/j.breast.2017.01.007","journal-title":"Breast"},{"issue":"3","key":"6972_CR24","doi-asserted-by":"publisher","first-page":"315","DOI":"10.21147\/j.issn.1000-9604.2018.03.04","volume":"30","author":"X Liu","year":"2018","unstructured":"Liu X, Ran R, Shao B, Rugo HS, Yang Y, Hu Z, Wei Z, Wan F, Kong W, Song G, Jiang H, Liang X, Zhang R, Yan Y, Xu G, Li H (2018) Combined peripheral natural killer cell and circulating tumor cell enumeration enhance prognostic efficiency in patients with metastatic triple-negative breast cancer. Chin J Cancer Res 30(3):315\u2013326. https:\/\/doi.org\/10.21147\/j.issn.1000-9604.2018.03.04","journal-title":"Chin J Cancer Res"},{"key":"6972_CR25","doi-asserted-by":"publisher","first-page":"866293","DOI":"10.3389\/fonc.2022.866293","volume":"12","author":"Y Zhou","year":"2022","unstructured":"Zhou Y, Zhou J, Xiao J, Wang Y, Wang H, Shi H, Yue C, Jia F, Li P, Hu Z, Yang Y, Jiang Z, Wang T (2022) Prognostic relevance of estrogen receptor status in circulating tumor cells in breast cancer patients treated with endocrine therapy. Front Oncol 12:866293. https:\/\/doi.org\/10.3389\/fonc.2022.866293","journal-title":"Front Oncol"},{"issue":"9","key":"6972_CR26","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1016\/j.molonc.2015.05.009","volume":"9","author":"M Mazel","year":"2015","unstructured":"Mazel M, Jacot W, Pantel K, Bartkowiak K, Topart D, Cayrefourcq L, Rossille D, Maudelonde T, Fest T, Alix-Panabieres C (2015) Frequent expression of PD-L1 on circulating breast cancer cells. Mol Oncol 9(9):1773\u20131782. https:\/\/doi.org\/10.1016\/j.molonc.2015.05.009","journal-title":"Mol Oncol"},{"issue":"8","key":"6972_CR27","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1093\/clinchem\/hvaa121","volume":"66","author":"W Jacot","year":"2020","unstructured":"Jacot W, Mazel M, Mollevi C, Pouderoux S, D\u2019Hondt V, Cayrefourcq L, Bourgier C, Boissiere-Michot F, Berrabah F, Lopez-Crapez E, Bidard FC, Viala M, Maudelonde T, Guiu S, Alix-Panabieres C (2020) Clinical correlations of programmed cell death ligand 1 status in liquid and standard biopsies in breast cancer. Clin Chem 66(8):1093\u20131101. https:\/\/doi.org\/10.1093\/clinchem\/hvaa121","journal-title":"Clin Chem"},{"issue":"2","key":"6972_CR28","doi-asserted-by":"publisher","first-page":"376","DOI":"10.3390\/cancers12020376","volume":"12","author":"MA Papadaki","year":"2020","unstructured":"Papadaki MA, Koutsopoulos AV, Tsoulfas PG, Lagoudaki E, Aggouraki D, Monastirioti A, Koutoulaki C, Apostolopoulou CA, Merodoulaki AC, Papadaki C, Mavroudis D, Agelaki S (2020) Clinical relevance of immune checkpoints on circulating tumor cells in breast cancer. Cancers 12(2):376. https:\/\/doi.org\/10.3390\/cancers12020376","journal-title":"Cancers"},{"issue":"11","key":"6972_CR29","doi-asserted-by":"publisher","first-page":"e0260124","DOI":"10.1371\/journal.pone.0260124","volume":"16","author":"EP Darga","year":"2021","unstructured":"Darga EP, Dolce EM, Fang F, Kidwell KM, Gersch CL, Kregel S, Thomas DG, Gill A, Brown ME, Gross S, Connelly M, Holinstat M, Cobain EF, Rae JM, Hayes DF, Paoletti C (2021) PD-L1 expression on circulating tumor cells and platelets in patients with metastatic breast cancer. PLoS ONE 16(11):e0260124. https:\/\/doi.org\/10.1371\/journal.pone.0260124","journal-title":"PLoS ONE"},{"issue":"7","key":"6972_CR30","doi-asserted-by":"publisher","first-page":"e1438111","DOI":"10.1080\/2162402X.2018.1438111","volume":"7","author":"C Yue","year":"2018","unstructured":"Yue C, Jiang Y, Li P, Wang Y, Xue J, Li N, Li D, Wang R, Dang Y, Hu Z, Yang Y, Xu J (2018) Dynamic change of PD-L1 expression on circulating tumor cells in advanced solid tumor patients undergoing PD-1 blockade therapy. Oncoimmunology 7(7):e1438111. https:\/\/doi.org\/10.1080\/2162402X.2018.1438111","journal-title":"Oncoimmunology"},{"issue":"2","key":"6972_CR31","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1158\/1078-0432.CCR-18-2484","volume":"25","author":"J Xu","year":"2019","unstructured":"Xu J, Zhang Y, Jia R, Yue C, Chang L, Liu R, Zhang G, Zhao C, Zhang Y, Chen C, Wang Y, Yi X, Hu Z, Zou J, Wang Q (2019) Anti-PD-1 Antibody SHR-1210 combined with apatinib for advanced hepatocellular carcinoma, gastric, or esophagogastric junction cancer: an open-label, dose escalation and expansion study. Clin Cancer Res 25(2):515\u2013523. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-2484","journal-title":"Clin Cancer Res"},{"issue":"12","key":"6972_CR32","doi-asserted-by":"publisher","first-page":"e2227","DOI":"10.1002\/onco.13981","volume":"26","author":"Z Tan","year":"2021","unstructured":"Tan Z, Yue C, Ji S, Zhao C, Jia R, Zhang Y, Liu R, Li D, Yu Q, Li P, Hu Z, Yang Y, Xu J (2021) Assessment of PD-L1 expression on circulating tumor cells for predicting clinical outcomes in patients with cancer receiving PD-1\/PD-L1 blockade therapies. Oncologist 26(12):e2227\u2013e2238. https:\/\/doi.org\/10.1002\/onco.13981","journal-title":"Oncologist"},{"issue":"17","key":"6972_CR33","doi-asserted-by":"publisher","first-page":"4685","DOI":"10.1158\/1078-0432.CCR-21-0327","volume":"27","author":"L Marcus","year":"2021","unstructured":"Marcus L, Fashoyin-Aje LA, Donoghue M, Yuan M, Rodriguez L, Gallagher PS, Philip R, Ghosh S, Theoret MR, Beaver JA, Pazdur R, Lemery SJ (2021) FDA approval summary: pembrolizumab for the treatment of tumor mutational burden-high solid tumors. Clin Cancer Res 27(17):4685\u20134689. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-0327","journal-title":"Clin Cancer Res"},{"issue":"5","key":"6972_CR34","doi-asserted-by":"publisher","first-page":"394","DOI":"10.18632\/oncotarget.27877","volume":"12","author":"TA O\u2019Meara","year":"2021","unstructured":"O\u2019Meara TA, Tolaney SM (2021) Tumor mutational burden as a predictor of immunotherapy response in breast cancer. Oncotarget 12(5):394\u2013400. https:\/\/doi.org\/10.18632\/oncotarget.27877","journal-title":"Oncotarget"},{"issue":"26","key":"6972_CR35","doi-asserted-by":"publisher","first-page":"4080","DOI":"10.1039\/c4tb00456f","volume":"2","author":"L Bai","year":"2014","unstructured":"Bai L, Du Y, Peng J, Liu Y, Wang Y, Yang Y, Wang C (2014) Peptide-based isolation of circulating tumor cells by magnetic nanoparticles. J Mater Chem B 2(26):4080\u20134088. https:\/\/doi.org\/10.1039\/c4tb00456f","journal-title":"J Mater Chem B"},{"issue":"4","key":"6972_CR36","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1158\/1535-7163.MCT-14-0983","volume":"14","author":"SP Patel","year":"2015","unstructured":"Patel SP, Kurzrock R (2015) PD-L1 expression as a predictive biomarker in cancer immunotherapy. Mol Cancer Ther 14(4):847\u2013856. https:\/\/doi.org\/10.1158\/1535-7163.MCT-14-0983","journal-title":"Mol Cancer Ther"},{"issue":"10","key":"6972_CR37","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1016\/j.ctrv.2015.11.001","volume":"41","author":"X Meng","year":"2015","unstructured":"Meng X, Huang Z, Teng F, Xing L, Yu J (2015) Predictive biomarkers in PD-1\/PD-L1 checkpoint blockade immunotherapy. Cancer Treat Rev 41(10):868\u2013876. https:\/\/doi.org\/10.1016\/j.ctrv.2015.11.001","journal-title":"Cancer Treat Rev"},{"key":"6972_CR38","doi-asserted-by":"publisher","first-page":"5023","DOI":"10.2147\/OTT.S105862","volume":"9","author":"X Wang","year":"2016","unstructured":"Wang X, Teng F, Kong L, Yu J (2016) PD-L1 expression in human cancers and its association with clinical outcomes. Onco Targets Ther 9:5023\u20135039. https:\/\/doi.org\/10.2147\/OTT.S105862","journal-title":"Onco Targets Ther"},{"issue":"6","key":"6972_CR39","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1080\/13543784.2022.2049232","volume":"31","author":"E Agostinetto","year":"2022","unstructured":"Agostinetto E, Losurdo A, Nader-Marta G, Santoro A, Punie K, Barroso R, Popovic L, Solinas C, Kok M, de Azambuja E, Lambertini M (2022) Progress and pitfalls in the use of immunotherapy for patients with triple negative breast cancer. Expert Opin Investig Drugs 31(6):567\u2013591. https:\/\/doi.org\/10.1080\/13543784.2022.2049232","journal-title":"Expert Opin Investig Drugs"},{"issue":"10265","key":"6972_CR40","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1016\/S0140-6736(20)32531-9","volume":"396","author":"J Cortes","year":"2020","unstructured":"Cortes J, Cescon DW, Rugo HS, Nowecki Z, Im SA, Yusof MM, Gallardo C, Lipatov O, Barrios CH, Holgado E, Iwata H, Masuda N, Otero MT, Gokmen E, Loi S, Guo Z, Zhao J, Aktan G, Karantza V, Schmid P, Investigators K (2020) Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet 396(10265):1817\u20131828. https:\/\/doi.org\/10.1016\/S0140-6736(20)32531-9","journal-title":"Lancet"},{"issue":"9","key":"6972_CR41","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1056\/NEJMoa1910549","volume":"382","author":"P Schmid","year":"2020","unstructured":"Schmid P, Cortes J, Pusztai L, McArthur H, Kummel S, Bergh J, Denkert C, Park YH, Hui R, Harbeck N, Takahashi M, Foukakis T, Fasching PA, Cardoso F, Untch M, Jia L, Karantza V, Zhao J, Aktan G, Dent R, O\u2019Shaughnessy J, Investigators K (2020) Pembrolizumab for early triple-negative breast cancer. N Engl J Med 382(9):810\u2013821. https:\/\/doi.org\/10.1056\/NEJMoa1910549","journal-title":"N Engl J Med"},{"issue":"16","key":"6972_CR42","doi-asserted-by":"publisher","first-page":"8057","DOI":"10.7150\/thno.59677","volume":"11","author":"A Rzhevskiy","year":"2021","unstructured":"Rzhevskiy A, Kapitannikova A, Malinina P, Volovetsky A, Aboulkheyr Es H, Kulasinghe A, Thiery JP, Maslennikova A, Zvyagin AV, Ebrahimi Warkiani M (2021) Emerging role of circulating tumor cells in immunotherapy. Theranostics 11(16):8057\u20138075. https:\/\/doi.org\/10.7150\/thno.59677","journal-title":"Theranostics"},{"issue":"7718","key":"6972_CR43","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1038\/s41586-018-0392-8","volume":"560","author":"G Chen","year":"2018","unstructured":"Chen G, Huang AC, Zhang W, Zhang G, Wu M, Xu W, Yu Z, Yang J, Wang B, Sun H, Xia H, Man Q, Zhong W, Antelo LF, Wu B, Xiong X, Liu X, Guan L, Li T, Liu S, Yang R, Lu Y, Dong L, McGettigan S, Somasundaram R, Radhakrishnan R, Mills G, Lu Y, Kim J, Chen YH, Dong H, Zhao Y, Karakousis GC, Mitchell TC, Schuchter LM, Herlyn M, Wherry EJ, Xu X, Guo W (2018) Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response. Nature 560(7718):382\u2013386. https:\/\/doi.org\/10.1038\/s41586-018-0392-8","journal-title":"Nature"},{"issue":"3","key":"6972_CR44","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1007\/s10549-016-4014-6","volume":"160","author":"JS Lee","year":"2016","unstructured":"Lee JS, Magbanua MJM, Park JW (2016) Circulating tumor cells in breast cancer: applications in personalized medicine. Breast Cancer Res Treat 160(3):411\u2013424. https:\/\/doi.org\/10.1007\/s10549-016-4014-6","journal-title":"Breast Cancer Res Treat"},{"issue":"45","key":"6972_CR45","doi-asserted-by":"publisher","first-page":"e1805344","DOI":"10.1002\/adma.201805344","volume":"31","author":"W Li","year":"2019","unstructured":"Li W, Wang H, Zhao Z, Gao H, Liu C, Zhu L, Wang C, Yang Y (2019) Emerging nanotechnologies for liquid biopsy: the detection of circulating tumor cells and extracellular vesicles. Adv Mater 31(45):e1805344. https:\/\/doi.org\/10.1002\/adma.201805344","journal-title":"Adv Mater"},{"issue":"21","key":"6972_CR46","doi-asserted-by":"publisher","first-page":"2460","DOI":"10.1200\/JCO.2015.64.8931","volume":"34","author":"R Nanda","year":"2016","unstructured":"Nanda R, Chow LQ, Dees EC, Berger R, Gupta S, Geva R, Pusztai L, Pathiraja K, Aktan G, Cheng JD, Karantza V, Buisseret L (2016) Pembrolizumab in patients with advanced triple-negative breast cancer: phase Ib KEYNOTE-012 study. J Clin Oncol 34(21):2460\u20132467. https:\/\/doi.org\/10.1200\/JCO.2015.64.8931","journal-title":"J Clin Oncol"},{"issue":"3","key":"6972_CR47","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1093\/annonc\/mdy518","volume":"30","author":"S Adams","year":"2019","unstructured":"Adams S, Loi S, Toppmeyer D, Cescon DW, De Laurentiis M, Nanda R, Winer EP, Mukai H, Tamura K, Armstrong A, Liu MC, Iwata H, Ryvo L, Wimberger P, Rugo HS, Tan AR, Jia L, Ding Y, Karantza V, Schmid P (2019) Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study. Ann Oncol 30(3):405\u2013411. https:\/\/doi.org\/10.1093\/annonc\/mdy518","journal-title":"Ann Oncol"},{"issue":"3","key":"6972_CR48","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1093\/annonc\/mdy517","volume":"30","author":"S Adams","year":"2019","unstructured":"Adams S, Schmid P, Rugo HS, Winer EP, Loirat D, Awada A, Cescon DW, Iwata H, Campone M, Nanda R, Hui R, Curigliano G, Toppmeyer D, O\u2019Shaughnessy J, Loi S, Paluch-Shimon S, Tan AR, Card D, Zhao J, Karantza V, Cortes J (2019) Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study. Ann Oncol 30(3):397\u2013404. https:\/\/doi.org\/10.1093\/annonc\/mdy517","journal-title":"Ann Oncol"},{"issue":"4","key":"6972_CR49","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/S1470-2045(20)30754-3","volume":"22","author":"EP Winer","year":"2021","unstructured":"Winer EP, Lipatov O, Im SA, Goncalves A, Munoz-Couselo E, Lee KS, Schmid P, Tamura K, Testa L, Witzel I, Ohtani S, Turner N, Zambelli S, Harbeck N, Andre F, Dent R, Zhou X, Karantza V, Mejia J, Cortes J, Investigators Group (2021) Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial. Lancet Oncol 22(4):499\u2013511. https:\/\/doi.org\/10.1016\/S1470-2045(20)30754-3","journal-title":"Lancet Oncol"},{"issue":"5","key":"6972_CR50","doi-asserted-by":"publisher","first-page":"517","DOI":"10.6004\/jnccn.2020.7543","volume":"18","author":"S Chumsri","year":"2020","unstructured":"Chumsri S, Sokol ES, Soyano-Muller AE, Parrondo RD, Reynolds GA, Nassar A, Thompson EA (2020) Durable complete response with immune checkpoint inhibitor in breast cancer with high tumor mutational burden and APOBEC signature. J Natl Compr Canc Netw 18(5):517\u2013521. https:\/\/doi.org\/10.6004\/jnccn.2020.7543","journal-title":"J Natl Compr Canc Netw"},{"key":"6972_CR51","doi-asserted-by":"publisher","first-page":"710596","DOI":"10.3389\/fonc.2021.710596","volume":"11","author":"F Braso-Maristany","year":"2021","unstructured":"Braso-Maristany F, Sanso M, Chic N, Martinez D, Gonzalez-Farre B, Sanfeliu E, Ghiglione L, Carcelero E, Garcia-Corbacho J, Sanchez M, Soy D, Jares P, Peg V, Saura C, Munoz M, Prat A, Vivancos A (2021) Case report: a case study documenting the activity of atezolizumab in a PD-L1-negative triple-negative breast cancer. Front Oncol 11:710596. https:\/\/doi.org\/10.3389\/fonc.2021.710596","journal-title":"Front Oncol"},{"issue":"1","key":"6972_CR52","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s10549-021-06421-2","volume":"191","author":"N Chic","year":"2022","unstructured":"Chic N, Braso-Maristany F, Prat A (2022) Biomarkers of immunotherapy response in breast cancer beyond PD-L1. Breast Cancer Res Treat 191(1):39\u201349. https:\/\/doi.org\/10.1007\/s10549-021-06421-2","journal-title":"Breast Cancer Res Treat"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-023-06972-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-023-06972-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-023-06972-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,5]],"date-time":"2023-06-05T14:08:53Z","timestamp":1685974133000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-023-06972-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,25]]},"references-count":52,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["6972"],"URL":"https:\/\/doi.org\/10.1007\/s10549-023-06972-6","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,25]]},"assertion":[{"value":"3 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Written informed consent was obtained from the parents.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}]}}